Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID

Volume: 17, Pages: 666 - 682
Published: Jun 1, 2020
Abstract
Recombinase-activating gene-1 (RAG1)-deficient severe combined immunodeficiency (SCID) patients lack B and T lymphocytes due to the inability to rearrange immunoglobulin and T cell receptor genes. Gene therapy is an alternative for those RAG1-SCID patients who lack a suitable bone marrow donor. We designed lentiviral vectors with different internal promoters driving codon-optimized RAG1 to ensure optimal expression. We used Rag1−/− mice as a...
Paper Details
Title
Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID
Published Date
Jun 1, 2020
Volume
17
Pages
666 - 682
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.